多囊卵巢综合征患者AMH水平与不良结局的相关性研究进展  

Progress in the Study of the Correlation between AMH Levels and Adverse Outcomes in Patients with Polycystic Ovary Syndrome

作　　者：闫美麟 匡洪影[2] 

机构地区：[1]黑龙江中医药大学研究生院,黑龙江 哈尔滨 [2]黑龙江中医药大学附属第一医院妇二科,黑龙江 哈尔滨

出　　处：《临床个性化医学》2024年第4期1640-1644,共5页Journal of Clinical Personalized Medicine

摘　　要：多囊卵巢综合征(PCOS)患者常伴随一系列并发症,包括但不限于不孕、流产、早产、胰岛素抵抗、高雄激素血症等,对患者的生活质量和生育能力构成显著影响。抗缪勒氏管激素(AMH)作为评估卵巢功能的重要指标,在临床上常被用作PCOS的评估指标。本文综述旨在深入探讨AMH水平在PCOS患者不良结局中的研究进展。Patients with polycystic ovary syndrome (PCOS) are often accompanied by a series of complications, including but not limited to infertility, miscarriage, preterm labor, insulin resistance, hyperandrogenemia, etc., which pose a significant impact on the quality of life and fertility of patients. Anti-Müllerian hormone (AMH), as an important indicator for assessing ovarian function, is often used clinically as an assessment indicator for PCOS. The aim of this review is to provide insight into the research progress of AMH levels in adverse outcomes of PCOS patients.

关 键 词：多囊卵巢综合征 抗缪勒氏管激素 排卵障碍 流产 早产 

分 类 号：R71[医药卫生—妇产科学]